Repurposing dipeptidyl peptidase-4 inhibitor for Parkinson's disease prevention: A drug-target Mendelian randomization study. [PDF]
Lee JY, Park DG, Sung J.
europepmc +1 more source
Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor. [PDF]
Kano Y, Kato M.
europepmc +1 more source
Associations of skeletal muscle mass and strength with arterial stiffness in type 2 diabetes
Lower skeletal muscle mass and lower handgrip strength were associated with higher arterial stiffness in individuals with type 2 diabetes. Assessment of both parameters may provide complementary information regarding vascular risk. ABSTRACT Sarcopenia is prevalent in people with type 2 diabetes mellitus (T2DM) and may contribute to increased ...
Naoki Koike +10 more
wiley +1 more source
Identification of distinct epitopes in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. [PDF]
Mai S +6 more
europepmc +1 more source
Adaptive islet biology and incretin physiology provide a framework linking diverse diabetes phenotypes, with advances in β‐cell stress adaptation, intra‐islet communication, receptor‐resolved biology, and β‐cell mass imaging. By integrating clinical perspectives from Asia and Europe with multiscale islet‐cell biology, these insights may support ...
Takaaki Murakami +5 more
wiley +1 more source
Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura. [PDF]
Kawamoto H +4 more
europepmc +1 more source
In 1,468 patients with type 2 diabetes, central obesity (WHtR >0.5) neutralizes the protective effects of higher BMI on muscle strength. Concurrently, visceral adiposity and CKD impose an additive threat, maximizing low handgrip strength risk (aOR = 1.74). Combining WHtR and renal tracking optimizes clinical sarcopenia screening.
Shing‐Hua Chen +4 more
wiley +1 more source
A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor. [PDF]
Fukata M +5 more
europepmc +1 more source
The influence of dipeptidyl peptidase-4 inhibitor on the progression of type B intramural hematoma. [PDF]
Chen Q, Jiang D, Shan Z.
europepmc +1 more source

